Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
- MHLW Unveils List of “Stable Supply Medicines”
March 2, 2021
- Nichi-Iko to Get Business Suspension Order on March 3
March 2, 2021
- MHLW Study Group Compiles Guideline for Collecting COVID-19 Convalescent Plasma
March 2, 2021
- 172 Vials of Pfizer Vaccine Unusable due to Freezer Breakdown
March 2, 2021
- MHLW Asks Municipalities to Secure Adrenaline Preparations for Anaphylaxis
March 1, 2021
- PAFSC Minutes for Pfizer Vaccine Disclosed
March 1, 2021
- Govt to Deliver 1st COVID-19 Vaccine Dose for 3.7 Million HCPs in April: Minister
March 1, 2021
- MHLW Orders Label Revisions for NSAIDs, Salbutamol, Kymriah
March 1, 2021
- Japan Research Group to Wrap Up Report on Clinical Trials for Cannabis-Derived Drugs by March-End
February 26, 2021
- Key Panel Gives Thumbs-Up to Teijin’s Osteoporosis Med, JCR’s Hunter Syndrome Drug and More
February 26, 2021
- Japan Might Ease Temperature Requirements for Pfizer Vaccine
February 26, 2021
- MHLW Panel Shelves Decision on Bayer’s Heart Failure Med Vericiguat
February 26, 2021
- CSL Plans Export of 2 Surplus Human Immunoglobulin Products
February 26, 2021
- 17,888 Doses of COVID-19 Vaccine Given in Japan as of Feb. 24
February 25, 2021
- Nichi-Iko Likely to Face Biz Suspension Order over Spate of Recalls
February 25, 2021
- MHLW Approves Add’l Use for Thaled, Bavencio and More
February 25, 2021
- 10,000 COVID-19 Patients Received Avigan in Observational Studies: Govt
February 25, 2021
- MHLW Formally Adopts GS1 Codes for Electronic Package Inserts; Rule to Take Effect August 1
February 25, 2021
- Japan to Start Elderly Vaccine Rollout from April 12: Minister
February 25, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…